Navigation Links
Researchers to identify genetic biomarkers for aggressive breast cancer
Date:9/11/2013

LOS ANGELES (Sept. 10, 2013) The Avon Foundation for Women has awarded a $300,000 grant to Dolores Di Vizio, MD, PhD, associate professor in the Department of Surgery and the Department of Pathology and Laboratory Medicine and a member of the Cancer Biology and Urologic Oncology Research Programs at the Cedars-Sinai Samuel Oschin Comprehensive Cancer Institute to advance scientific research in aggressive breast cancer.

Di Vizio will collaborate with the Cedars-Sinai Women's Cancer Program to investigate biomarkers in patient blood samples that may identify individuals with aggressive breast cancer. Biomarkers are genes or other molecules that can indicate a person's predisposition to specific medical conditions.

Research findings have the potential to create a novel standard of care and a new source of biomarkers. The possible new source of biomarkers, known as large oncosomes, are tumor-derived vesicles that transmit signaling complexes between cell compartments, providing valuable insight into the progression of disease. Findings may also help researchers and clinicians predict the aggressiveness of breast cancer earlier in the diagnostic process.

"This kind of research is the essential foundation to get us to our real goal, which is to improve diagnostic and prognostic capabilities and find effective treatments for breast cancer," said Di Vizio. "With this study, we hope to identify previously unrecognized large oncosomes as potential biomarkers in advanced tumors that can be visualized, quantified and isolated using methods easily translatable to the clinic."

Funding from the Avon Foundation for Women, a nonprofit organization and longtime supporter of Cedars-Sinai, will provide an opportunity for researchers to further spearhead new technologies, therapies and surgical interventions that may provide better patient outcomes, beginning at diagnosis.

Working with Di Vizio to provide these advancements is collaborator Beth Y. Karlan, MD, director of the Women's Cancer Program, director of the Division of Gynecologic Oncology in the Department of Obstetrics and Gynecology, the Cedars-Sinai Board of Governors Chair in Gynecologic Oncology and the director of the Cedars-Sinai Gilda Radner Hereditary Cancer Program.

"I'm excited to be a collaborator on this research study, as it holds promise to provide tangible improvements in earlier diagnostics and detection in aggressive breast cancer and is perfectly aligned with the program goals of the Cedars-Sinai Women's Cancer Program," said Karlan. "This Avon Foundation for Women grant will further our program's commitment to studying cancer biology, developing new approaches to early detection and preventing and improving cancer survival for all patients."

This is the first study on large oncosomes analyses in patients with breast cancer. Pilot funding for this grant is supported by the Martz Breast Cancer Discovery Fund.


'/>"/>

Contact: Cara Lasala
cara.lasala@cshs.org
310-423-7798
Cedars-Sinai Medical Center
Source:Eurekalert

Related medicine news :

1. Researchers link obesity and the bodys production of fructose
2. Researchers find whats missing in teen health programs
3. UCLA researchers describe new form of irritable bowel syndrome
4. Researchers study survival in African American versus Caucasian lung cancer patients
5. Researchers develop specific tests to identify cancer biomarkers in dermatomyositis
6. Medical Researchers Say They Have Made a Breakthrough That Could Lead to a Potential Cure for AIDS
7. Researchers identify new drug target for treating jet lag and shift work disorders
8. BUSM researchers call for individualized criteria for diagnosing obesity
9. Brain Size May Signal Risk of Developing an Eating Disorder, CU School of Medicine Researchers Look at Brain Size and Eating Disorders
10. Researchers Discover a Potential Cause of Autism
11. ASTRO awards $34,500 in individual grants to top researchers presenting at the 2013 Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2017)... ... February 26, 2017 , ... This is ... the world’s first to be ISO/IEC 17025:2005 INAB accredited for Der p 1 ... 17025:2005 is the globally recognised standard that sets out requirements for the technical ...
(Date:2/26/2017)... ... February 26, 2017 , ... ... in North America, today announced it would be offering some it’s exclusive product ... itself on crafting quality and unique baby clothing/feeding products, will team up with ...
(Date:2/26/2017)... ... February 26, 2017 , ... ... and reporting for healthcare organizations. This comprehensive and customizable solution empowers StaffBridge ... StaffBridge technology improves staffing efficiency, maximizes resource allocation, collects critical reporting data, ...
(Date:2/26/2017)... ... February 26, 2017 , ... Functional imaging data supports ... a study released today at the 1st Pan American Parkinson’s and Movement Disorders ... be effective in improving cognitive function in PD patients. This study, led by ...
(Date:2/25/2017)... ... , ... FCPX users now have the ability to sharpen a desired color ... users have total control over sharpening amount, sharpening radius, threshold, horizontal sharpening, vertical sharpening, ... users can visually see the color range effected with ease all within Final ...
Breaking Medicine News(10 mins):
(Date:2/27/2017)... 2017  RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the ... focused on tissue protection, repair and regeneration, today ... Ltd., received a positive response from the U.S. ... for RGN-137 to treat epidermolysis bullosa ("EB"). RGN-137 ... Thymosin beta 4 ("Tß4") as the active pharmaceutical ...
(Date:2/27/2017)... -- Now in its seventh year, the Pharmaceutical ... successful at developing and commercialising innovation. ... The Index can be summarised ... two different companies in early phase, which would make the ... of each company,s performance between 2011 and 2016, the 2017 ranking sees ...
(Date:2/27/2017)... , February 27, 2017 Leading Countries, ... market is expected to grow at a CAGR of 8.9% ... expected to grow at a CAGR of 9.1% from 2016 to ... in 2027. ... this report will benefit you Read on to discover how ...
Breaking Medicine Technology: